SUPPORT AND RESOURCES FOR YOUR PATIENTS AND YOUR PRACTICE
ILUMYA® (tildrakizumab-asmn) set a new benchmark as the IL-23 inhibitor with the first and longest complete data set from 2 Phase 3 clinical trials for moderate-to-severe plaque psoriasis.1
Hear Dr. George Han, M.D., System Medical Director for Dermatology at the Mount Sinai Health System and Dr. Stephen Rozzo, Ph.D., Senior Director of Dermatology Medical Affairs at Sun Pharma discuss what impact this 5-year efficacy and safety data from ILUMYA® could have on the future of IL-23 inhibitors in the treatment of moderate-to severe plaque psoriasis.
Short on time? Learn about the key attributes of ILUMYA® in under 4 minutes. This dynamic video showcases the most important information you need to know about the long-term efficacy, durable safety, quarterly dosing, and mechanism of action of ILUMYA®.
— New version with 5-year data updates! —
Watch the video below to see a healthcare professional (Dr. George Han) properly inject ILUMYA®, learn about the dosing benefits of ILUMYA®, and see a dosing comparison of different regimens for the treatment of moderate-to-severe plaque psoriasis.
Watch this video in 3D animation to see how ILUMYA® precisely targets the IL-23 pathway of the inflammatory cycle of psoriasis.
INDICATION AND IMPORTANT SAFETY INFORMATION
ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.
ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.
Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.
The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.
Please see full Prescribing Information.